Matinas BioPharma Holdings, Inc.
MTNBAMEXHealthcare● Active
$0.83
+$0.04(+5.20%)
Market Cap$4609530
P/E Ratio—
52W High$3.09
52W Low$0.48
Matinas BioPharma Holdings, Inc. (MTNB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MTNB · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.02B | $0.01B |
| Gross Profit | $0.00B | $0.00B | $0.00B | ($0.01B) | ($0.01B) |
| Gross Margin %(computed) | — | — | 100.00% | -423.15% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.01B | $0.01B | $0.02B | $0.01B |
| G&A Expenses | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Total Operating Expenses | $0.01B | $0.02B | $0.02B | $0.01B | $0.01B |
| Operating Income | ($0.01B) | ($0.02B) | ($0.02B) | ($0.02B) | ($0.02B) |
| Operating Margin %(computed) | — | — | — | -771.33% | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.02B) | ($0.02B) | ($0.02B) | ($0.02B) |
| Income Tax Expense | $0.00B | ($0.00B) | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.02B) | ($0.02B) | ($0.02B) | ($0.02B) |
| Net Margin %(computed) | — | — | — | -658.63% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.00 | $-4.98 | $-5.28 | $-3.00 | $-5.04 |
| Wtd Avg Shares | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.01B) | ($0.02B) | ($0.02B) | ($0.02B) | ($0.02B) |
| EBITDA Margin %(computed) | — | — | — | -760.16% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Matinas BioPharma Holdings, Inc. data
About Matinas BioPharma Holdings, Inc. (MTNB) Income Statement
Matinas BioPharma Holdings, Inc. (MTNB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MTNB reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
MTNB · 4 questionsMatinas BioPharma Holdings, Inc. (MTNB) reported revenue of $0.00B for 2025, down —% year-over-year.
MTNB revenueMTNB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08